J
Julian R. Molina
Researcher at Mayo Clinic
Publications - 217
Citations - 16715
Julian R. Molina is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 47, co-authored 203 publications receiving 13224 citations. Previous affiliations of Julian R. Molina include University of Colorado Boulder & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S. Herbst,Paul Baas,Dong Wan Kim,Enriqueta Felip,Jose Luis Perez-Gracia,Ji Youn Han,Julian R. Molina,Joo Hang Kim,Catherine Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Gilberto de Castro,Marcelo Garrido,Gregory M. Lubiniecki,Yue Shentu,Ellie Im,Marisa Dolled-Filhart,Edward B. Garon +18 more
TL;DR: In this article, the authors evaluated the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Journal ArticleDOI
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
TL;DR: The introduction of angiogenesis, epidermal growth factor receptor inhibitors, and other new anti-cancer agents is changing the present and future of this disease and will certainly increase the number of lung cancer survivors.
Journal ArticleDOI
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
TL;DR: The results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLCs.
Journal ArticleDOI
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
Alex A. Adjei,Roger B. Cohen,Wilbur A. Franklin,Clive Morris,David S. Wilson,Julian R. Molina,Lorelei J. Hanson,Lia Gore,Laura Q M Chow,Stephen Leong,Lara Maloney,Gilad Gordon,Heidi Simmons,Allison L. Marlow,Kevin Litwiler,Suzy Brown,Gregory Poch,Katie Kane,Jerry Haney,S. Gail Eckhardt +19 more
TL;DR: AZD6244 was well tolerated with target inhibition demonstrated at the recommended phase II dose and PK analyses supported twice-daily dosing, and prolonged SD was seen in a variety of advanced cancers.
Journal ArticleDOI
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Yucai Wang,Shouhao Zhou,Shouhao Zhou,Fang Yang,Xinyue Qi,Xin Wang,Xiaoxiang Guan,Xiaoxiang Guan,Chan Shen,Narjust Duma,Jesus Vera Aguilera,Ashish V. Chintakuntlawar,Katharine A. Price,Julian R. Molina,Lance C. Pagliaro,Thorvardur R. Halfdanarson,Axel Grothey,Axel Grothey,Svetomir N. Markovic,Grzegorz S. Nowakowski,Stephen M. Ansell,Michael L. Wang +21 more
TL;DR: Different PD-1 and PD-L1 inhibitors appear to have varying treatment-related adverse events; a comprehensive summary of the incidences of treatment- related adverse events in clinical trials provides an important guide for clinicians.